Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Highlights

News from the human genome


The 1 April edition of Science announced the publication of the human genome with the previously-missing 8% now added to it. Comments from the Genopole Director of Research.
Read the special edition of Science « Completing the human genome » >
Human Genome - Genoscope Human Genome - Genoscope

The first—mostly complete—sequence of the human genome, of which chromosome 14 was decoded in France by Genoscope, was published eleven years ago, and the adventure continues today. Indeed, in an article dated 31 March 2022 and earning the cover of the 1 April edition of Science, the international Telomere-to-Telomere Consortium reported sequencing the 8% of the human genome that had remained unaddressed. Genopole Research & Platforms Director Christophe Lanneau discusses this important advancement.

Under the codename GRCh38, the most recent human genome reference sequence represented a consensus of several different genomes that had progressively enriched the very first sequence established in 2001. Despite that headway, 8% of the human genome had remained inaccessible because it was composed of highly-repetitive sequences that eluded discrimination and ordering by sequencing techniques*.

Today however, using novel sequencing technologies able to read very long sequences, the Telomere-to-Telomere consortium has filled in those holes. That consortium was created in 2019 with the objective of gaplessly reading each chromosome from one end (the “telomere”) to the other.

Genopole Research & Platforms Director CitationChristophe Lanneau, analyzes this major scientific breakthrough:
« This new human genome reference assembly, called CHM13, provides a very precise map of the highly-repetitive DNA sequences. It determined more than 225 million additional base pairs in a genome counting 3.1 billion. These highly-repetitive regions had remained inaccessible and received insufficient attention for many years. However, we’ve now come to realize their importance in cellular function and some of their roles in disease. This work is a major step forward for science.

These repetitive sequences are found mainly in two key regions of the chromosome: the centromere, a central region that plays a role in cell division and the correct transmission of the chromosome to the daughter cell, and the telomeres, the ends of the chromosome, that shorten as cells age and thus regulate their lifespans.

Being able to explore these sequences will yield new discoveries as to the genetic diversity they contain. These previously hidden sequences are also involved in epigenetic modifications. Epigenetics describes reversible and potentially inheritable mechanisms able to modify gene expression without modifying the underlying code. Epigenetics adapts gene expression to the environment or cell function. An increasing amount of evidence supports its role in organism function and adaptation.

Thus, with the rapidity of Illumina’s next-generation sequencing technology, researchers will be able to generate genomes in a matter of hours while benefiting in parallel from the quality and exhaustivity of this new reference sequence to better understand and interpret DNA sequences. »

In an interview with the newspaper Le Figaro, Citationthe director of the National Center of Human Genomics Research Jean-François Deleuze, underlines the importance of this work for «understanding key biological mechanisms.» He adds:«With current sequencing methods, we understand only about 50% of genetic diseases. Now, we may finally be able to better explain certain orphan diseases.»

In conclusion


Having a nearly-totally complete sequence of the human genome will contribute immeasurably to a better understanding not only of human evolution and cellular multiplication & differentiation but also of a range of diseases including cancers, cardiovascular diseases and many more.
Progress remains necessary in the determination of individual genetic diversity in human populations and the exploration of the y chromosome (resulting in male sex), which, for technical reasons, remains out of the reach of the technology deployed in the study.

  • * Genome sequencing technologies

    Genome sequencing describes the determination of the specific order of the “bases” (adenine (A), cytosine (C), guanine (G), and thymine (T)) that constitute the DNA sequence. Next-generation sequencing (NGS), developed notably by Illumina, involves cutting the genome into small fragments of about 100 base pairs then reading them individually. Because the cuts do not occur in the same place across different cells, the identification of identical sequence ends enables the reassembly and reconstitution of the DNA sequence via computerized analysis.

    More recently, the Oxford Nanopore technology has made it possible to read sequences with several tens of thousands of base pairs and even more. This technology involves forcing the passage of a DNA fragment through a nanometer-wide pore carrying an electrical current, which is modified in a specific manner by the passage of each base (A, C, G or T). Those current modifications progressively reveal the DNA sequence.

    Pacific Biosciences’ technology is also able to read sequences of at least 20,000 base pairs with 99.9% precision.

Reference

Special edition of Science « Completing the human genome »

Article posted on 4 April 2022

Share
Highlights

The latest news


Ibisc - Genopole's Laboratory

Optimizing the vital debriefing step in virtual reality training

The IBISC laboratory has developed an immersive debriefing module for virtual reality training and demonstrated its ability to optimize the vital debriefing step in that setting.

Discover
Genopole Partnering Week 2024 - un format hybride au service des biotechs

Partnering Week 2024: a hybrid edition for biotech innovation

Discover the highlights of Genopole Partnering Week 2024 (#GPW2024): a hybrid event bringing together start-ups, investors, and industry leaders to accelerate biotech innovation in health and the environment.

Discover
L'équipe de la Biofonderie de Paris dont Genopole est membre au GBA 2024 en Corée

Genopole’s actions for synthetic biology and the bioeconomy

Genopole strengthens its key roles in synthetic biology, biomanufacturing and the bioeconomy, as demonstrates its notable actions carried out this fall on several national and international scenes.

Discover
Mission Bio Japan 2024 : Abolis Biotechnologies et Ispiron, accompagnées par Laurence Lacroix-Orio, directrice du Pôle Croissance et Prospection de Genopole, Paul Caroën, Program Manager et Alexis Biton, coordinateur des affaires internationales

Genopole’s mission to Japan – a country looking to lead in bioindustry

Genopole's mission to Japan was a great opportunity to extend its international network of investors and corporations in Eastern Asia. It is opening itself to partnerships with foreign start-ups to strengthen the commercial deployment of innovative breakthroughs for regenerative medicine, gene editing and artificial intelligence.

Discover
Les projets immobilier du biocluster Genopole - Evry

Real estate at Genopole: supporting growth through a strategic offer for workspace

With more than 41,000 m² of office and lab premises & more than seven hectares of available land tracts, the real estate offer of the Genopole biocluster is actively laying the groundwork for future developments with projects such as GenoLife and Cube.

Discover
Généthon - Vers une nouvelle génération de vecteurs viraux AAV pour la thérapie généique

The road toward a new generation of gene therapy vectors

Using an AI approach, Genethon has conceived a next-generation vector improving the specificity and safety of gene therapies for muscular dystrophies.

Discover

Protopia: Genopole steps into a new era of prototyping

Protopia, a new, advanced prototyping platform aimed at transforming R&D in biotech sectors, will be a resounding next-step in support for innovative biotech start-ups and businesses. It aims to accelerate project upscaling and preindustrialization while also empowering interdisciplinary partnerships.

Discover
Equipe du laboratoire LBEPS

LBEPS : Athletic performance is also forged in the laboratory

Research performed at LBEPS has resulted in three publications illustrating how a scientific approach to exercise can optimize athletic performance and health.

Discover
Laboratoire de R&D - Abolis - campus Genopole

Abolis raises €35 million from an international consortium

Abolis has reached another milestone in its upscaling objectives. Convinced by the pertinence and robustness of its technology, an international consortium of industrials and funders will provide €35 million to the company.

Discover
Hélène Virasith, Program manager à Genopole, a accompagné trois startups génopolitaines Nutropy, AuraLIP et Onima au salon Futur Food Tech de Chicago - Juin 2024

Genopole at the Future FoodTech 2024 – Chicago

Genopole was in Chicago on June 17 and 18 for the Future Food Tech conference. Genopole® accompanied three of the biocluster's companies developing more sustainable food: Nutropy, AuraLIP and Onima. This was an opportunity for them to get noticed by major US groups and investors, and to gain an insight into North American market trends.

Discover
La délégation Genopole à BIO USA 2024

Genopole at BIO International 2024

The Genopole team at the BIO International Convention in San Diego pursued three main objectives: promote Genopole accompaniment to attract new talent, highlight biocluster companies and gather information on market and regulatory tendencies.

Discover
ACS Publication - Cover May 2024 - qui contient la publication du Lambe sur les nanopores

Lambe: A new milestone on the path to nanopore-based precision diagnostics

June 2024- Lambe has demonstrated the ability of an aerolysin nanopore to discriminate enantiomeric forms of peptide biomarkers useful for medical diagnostics.

Discover
Visite de la délégation

Genopole and the Netherlands: together to accelerate the development of alternative proteins

Genopole welcomed a Dutch delegation of close to 20 company representatives and alternative proteins researchers. The objective of the visit was to explore possibilities for research and business partnerships aimed at the development of new foods capable of meeting the future's nutritional, environmental, health, business and gustatory demands.

Discover
Adnam Imeri et Jennifer Allouche, lauréats du programme financier ATIGE, créent leur équipe de recherche à Genopole respectivement en génomique et en biothérapies.

Two new research teams working on important subjects in genomics and innovative biotherapies

With its two new Atige laureates, Adnam Imeri and Jennifer Allouche, lauréats du programme financier ATIGE, create their research teams working on important subjects in genomics and innovative biotherapies.

Discover
le programme national d’envergure PEPR Biothérapies et Bioproduction,  co-piloté par Cécile Martinat, est piloté par le CEA et l'Inserm

Four biocluster labs involved in the PEPR national program

Launched in late 2023 as part of the France 2030 plan, the PEPR "Biotherapies and Biomanufacturing" program seeks to place France as the spearhead of the key sector of biodrugs. Three of the program's priority projects are headed by Genopole laboratories.

Discover
©Lionel Antoni - Plateforme d'irradiation expérimentale du LRGK - Plateforme génopolitaine mutualisée avec les acteurs de la communauté scientifique francilienne

The Experimental Irradiation Platform to serve the Île-de-France scientific community

Genopole is making available to the Île-de-France scientific community an Experimental Irradiation Platform equipped with a state of the art generator

Discover
Laina Freyer directrice scientifique, Felome

Felome Launches the Commercialization of Genetic Analyses for Companion Cats

Felome will begin the commercialization of a service offering genetic analyses for companion cats, to reveal their predispositions to over 50 diseases, identify their main physical traits, and their similarities with 14 types of breeds.

Discover
Lauréats de la promo 3 du programme Gene.iO - Genopole

Three Gene.iO whiz kids rewarded for their innovations

Three Gene.iO whiz kids, Alga Biologics, Fungu'it and Alt Biotech, rewarded for their innovations. Alga Biologics was among the 35 start-ups included in the French Blue Tech Index. Fungu'it and Alt Biotech, were selected to participate in 212 Founders, a start-up accompaniment and financing program by CDG Invest.

Discover
l'équipe iGEM 2023 Evry Paris-Saclay - Médaille d'or et p

A prize and gold for the 2023 Évry Paris-Saclay iGEM team

The international synthetic biology competition iGEM celebrated its 20th anniversary. From across the globe, the event drew more than 7,000 students in 400 teams from 66 countries. Genopole was there, among other actors in synthetic biology, to present the biocluster's advantages at its stand, and support the 17 students of the Évry Paris-Saclay team and their outstanding project, OptoGenEYEsis.

Discover
Genopole en mission exploratoire au Japon et en Corée du sud - octobre 2023

An exploratory mission to Japan and South Korea for Genopole

Genopole sent a team to Japan and South Korea to present itself and several of its accompanied businesses to major pharmaceutical corporations, investors and Asian bioclusters curious about biotechnological innovations and open to international partnerships.

Discover
View all >
With the support from
Région île de France